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Abstract
Lab-on-a-chip technology has been long envisaged to have tremendous commercial potential, owing to the ability of such devices 
to encapsulate a full range of laboratory processes in a single instrument and operate in a portable manner, rapidly and at low cost. 
Devices are believed to have potential in fields ranging across medical diagnostics, environmental sampling and a range of 
consumer products, however, to date very few devices have attained commercial success. This review examines the challenges 
relating to the commercialization of lab-on-a-chip technology from fundamental research to mass manufacturing and aims to 
provide insight to both academics and product development specialists the perceived hindrances to commercialization and a 
strategy by which future work could be translated into commercial success. 
© 2015 The Authors. Published by Elsevier B.V.
Peer-review under responsibility of School of Engineering, Faculty of Science Engineering & Built Environment, Deakin 
University.
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1.0 Introduction
In the recent decades technologies evolving from the translation of microsystems and microelectronics 
manufacturing techniques have led to the creation of a variety of novel devices with the ability to encapsulate a variety 
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of laboratory processes into a singular miniaturized platform, the so called, lab-on-a-chip. The field of lab-on-a-chip, 
and its related microsystems counterpart technologies (microfluidics, MEMS/NEMS, μTAS, etc) have now developed 
into truly multidisciplinary fields, requiring equal contributions from fields ranging across biology, chemistry, 
software development, physics and material science, in addition to the traditional skills of microfabrication and 
engineering used in their original inception and development. It is worth perhaps re-iterating at this point what is 
generally understood as lab-on-a-chip or microfluidics technology, which in itself highlights a confusion in technology 
translation, that there is no one single definition or indeed terminology by which all facets of this technology can be 
neatly expressed or pigeonholed. Lab-on-a-chip technology essential comprises devices which have an element that 
is millimeter to centimeter sizes which encapsulate more than one laboratory processes into a singular device. Such 
devices typically comprise microfluidic elements for fluid handling and additional components for fluid control, 
processing and some detection capability. Though here we make reference to lab-on-a-chip, this same definition could 
hold true for μTAS, etc and so these technologies should not be considered as mutually exclusive but belong to the 
same technological family.
Lab-on-a-chip, enabled by the complimentary use of microfluidics and biosensing has long been speculated to be 
one of, if not the definitive, methods by which laboratory based chemical and biological techniques can be integrated 
into miniaturized, low-cost analytical devices for portable  diagnostics in a range of sampling scenarios (medicine, 
environmental, etc). The market for microfluidic devices has been estimated to have a net value of $1.6 billion and is 
forecast to rise to $3.6-5.7 billion by 2018 [1], representing a significantly large commercial opportunity for this 
sector. Despite the promise and maturity of the technology, which has spanned several decades since the landmark 
first generation work by Terry et al 1979 [2] and later by Manz et al 1990 [3], the vast majority of systems have yet 
to be realized into commercial products or as ubiquitous tools used routinely as research grade instrumentation outside 
of specialist laboratories. The reason for the lack of immediate uptake of lab-on-a-chip technology despite it abundant 
advantages in sample processing have been somewhat of an enigma and have been the subject of debate by many of 
the prominent members of the scientific community [4]. Where lab-on-a-chip technology has been more successful 
has arguable been less as fully integrated devices for a bespoke purpose, over use as enabling tools for research 
endeavor or specialize fluid processing applications, with several companies worldwide offering such services 
(Dolomite, Microfluidic ChipShop, Minifab, etc).
There are however notable exceptions to this trend and a handful of lab-on-a-chip devices have successfully made 
it to the market and are ubiquitous in our daily lives, the most obvious examples being the humble inkjet printer 
cartridges and the home pregnancy test kit (although not traditionally perceived as but satisfying the technological 
specifications of lab-on-a-chip). More niche examples can also be found, such as microarrays and specialist medical 
diagnostics devices such as the Triage® cardiac panel (BiositeInc, USA) [5] and the i-Stat (Abbott Laboratories, 
USA). It is somewhat unclear why these devices have been more successful than their more modern and more 
integrated functionality modern counterparts, but it is believed we are converging closer to the answers. With respect 
to devices such as the Triage® cardiac panel and i-Stat, despite their well-developed technology, proven functionality 
and aesthetically pleasing designs, their uptake as the benchmark device/technique of preference in their intended 
utility within a clinical capacity, has been limited. The reason for this are multi-fold, but primarily are attributed to 
cost constraints for a given hospital/clinic and issues relating to user training/clear route for information relay, which 
ultimately don’t provide clinicians an added value which far exceeds current practices. This point is echoed in a recent 
commentary on microfluidic commercialization by Volpatti et al 2014, where they stress the importance to the 
community to strive forward with research into the pressing needs where microfluidics is not only the best, but the 
only solution for a given challenge [1]. Holger Becker in an article series for the journal Lab-on-a-chip, based around 
the theme of commercialization of microfluidics, very eloquently and insightfully addresses many of the key 
challenges and factors relating to the slow uptake of such technology [7-12]. This series provided valuable insights 
into the perception of the technology and how due to a complex interplay of the economy of scale in mass 
manufacturing, IP issues, lack of standardization, early inflated technological expectations that failed to materialize 
and several other crucial factors, the microfluidics industry has yet to flourish to its full potential. He also raises 
thought provoking debate as to whether there is such a thing as the ‘killer application’ in microfluidics, a comment 
mirrored in an earlier industry focus of microfluidics by Carsten Haber in 2006 [13]. In terms of commercialization 
of microfluidics the ‘killer application’ factor has likely played a major role in the reluctant uptake of the wealth of 
promising research based lab-on-a-chip technology, as investors are likely opting for alternative technologies with 
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higher profit margins and a more well defined route to market [1]. So what is the solution?
2. Unresolved challenges
Lab on a chip technology has reached a staggering level of maturity, with a multitude of ingenious devices and 
individual components allowing for a variety of complex chemical and biological assays to be performed in a single 
device, rapidly and with matching sensitivity to their traditional lab based counterparts. In the pursuit of engineering 
excellence in areas such as added device functionality, increased endpoint detection sensitivities and lower resolution 
manufacturing processes from the micro to the nanoscale, many academic researchers are found guilty of leaving the 
challenge of technology transfer into a commercially viable product as an afterthought over being a critical 
consideration of the overall engineering process chain. It is therefore believed that researchers in the lab-on-a-chip 
community need to focus less on further demonstrations of advanced functionality, but more on the challenge of 
integration, standardization, economy of scale for mass market appeal and, perhaps more importantly, the added value 
to the application the device is aimed towards.
2.1 Systems integration
The untold reality of many lab-on-a-chip devices are that such devices require the use of ancillary equipment 
such as fluidic pumps, high current power supplies, signal acquisition devices (microscopes, spectrometers, etc), with 
which to operate. Most of these devices are significantly larger than the lab-on-a-chip systems themselves, typically 
taking up a significant volume of space on a laboratory bench, negating many of benefits related to device 
miniaturization. This has led to the commonly heard pun and inspiration for the title of the article ‘it’s not a lab-on-a-
chip but a chip-in-a-lab’. If we consider the implementation of such systems into practical, usable areas, such as the 
point of care or even within specialist laboratories, such instrumentation would generally require the use of a skilled 
user. This introduces complications pertaining to user training and standardization protocols for use, a lack of 
portability, and the hiring of a skilled technician for operation and device maintenance, all of which hinder the uptake 
of the technology in the mainstream. Over the last two decades, individual lab-on-a-chip components have been 
comprehensively demonstrated and so to some degree it is considered trivial combining these into a singular, 
integrated device, be it on occasion at the expense of portability, usability, simplicity of manufacturing or cost. What 
must be recognized is that for commercial applications, technologies that do not readily allow a device to overcome 
the ‘chip in a lab’ bottleneck must sadly be disregarded over what may be more simplistic but crucially more practical 
technology with usability and seamless integration of components as its core attributes. With respect to fluidic 
processing, the difficulty can generally lie in the so called ‘chip-to-world’ interface by which the sample is introduced, 
the fluidic handling system and the actuation method to deliver and control fluids within a chip. For the vast majority 
of cases fluids are introduced though the use of a micro port and tubing, where flow is achieved through a mechanical 
pumping mechanism (e.g syringe pumps). Researchers have realized the use of on-chip pumps and valves for flow 
control, however, the issue of the chip to world interface still remains, in addition to the added fabrication complexity 
which may not readily translate to mass manufacturing. Commentators on the commercialization of microfluidics 
have been discussing the importance of world-to-chip interface for nearly a decade now [13] and only more recently 
are we seeing this issue being addressed. With respect to greater commercialization potential and as with the issue of 
the chip-in-a-lab conundrum, the chip-to-world interface must be addressed from the initial design phase with the aim 
of making the device as ‘user friendly’ as possible. Looking again at commercially successful examples this is readily 
demonstrated in the case of inkjet cartridges being simple plug and play systems and in the home pregnancy test kit 
which simply requires the loading of a sample onto the lateral flow membrane. Another less exploited area of 
integration, is to tailor devices to operate within existing systems where fluidic sample handling is already taking 
place, such as within livestock milking stations and chemical processing plants. In these examples there is an 
integrated infrastructure for fluid handling that could suit the addition of modular based components that could be 
integrated into the existing supply lines within the process chain. It is speculated that such instrumentation may depart 
from the traditional notion of ‘chip’ based devices but share all the same technology of current counterparts. 
Advantageously, such devices would likely complement existing technology in the target market, requiring the 
minimal of technology investment and alteration of existing practices, thus potentially allowing a greater level of 
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market acceptance and uptake. Finally a more interesting area of integration which is becoming more prevalent in the 
research community is the synergistic use of current ubiquitous technologies with their own innovations, such as 
replacing the use of a bespoke photodetector and data analysis system with the use of a camera and the computation 
ability of a mobile phone [14]. The elegance of this methodology is that not only is the overall design simplified and 
the cost reduced through reduction of the components required, but consideration is made to simplify the user interface 
(generally an intuitive app) and the management of data (processing and transmission through the phones 
connectivity). Such innovations may potentially increase the accessibility of lab-on-a-chip devices into the mainstream 
through complimentary use of ubiquitous devices, which added to the reduction in componentry for the overall device, 
enhances the commercial potential and market acceptance. It is anticipated that such dual use functionality and 
interconnectivity of devices will become more prevalent in the future for not only lab-on-a-chip, but most consumer 
devices, and should be a consideration academics should take note of.
2.2 Economies of Scale
Researchers generally aim to prove a hypothesis and do so in a single minded manner without worrying about 
issues such as economies of scale, with the field of lab-on-a-chip being no exception. Many innovations can be guilty 
of high degrees of complexity in the fabrication of individual components, and the complete device may require 
several highly specialized and labor intensive manufacturing techniques. Fabricating such devices generally draws 
more on the skill and experience of an individual user, across several interactive process, rather than being something 
which can be streamlined into a single manufacturing process. Examples of such high complexity systems are those 
which comprise components such as micro actuation systems (valves, pumps, etc) and fluid storage reservoirs coupled 
with microfluidics, while the device can also require complex surface modifications (e.g bonding, bio-fouling 
coatings, etc) and the binding of organic biorecognition elements on a single chip. Many traditional fabrication 
methods used to create micro and nano scale structures, such as lithographical techniques, do not translate well into 
large scale production. Additionally, backend processes (assembly, bonding, surface modifications, etc) and quality 
control at large scales volumes can contribute up to 80% of total production costs [8]. Therefore high complexity 
research based methodologies are generally at odds with what production and manufacturing personnel would see as 
satisfactory, where it is more desirable to reduce complexity to the bare minimum. It is therefore envisaged that for a 
system with a perceived commercial application, researchers from the design phase should opt for fabrication 
techniques that are readily up-scaleable, using designs which minimize the complexity and process stages required for 
backend processing. In addition to the design and fabrication, the choice of materials becomes crucial, particularly 
with respect to the cost and the desirable intrinsic material properties for the application in question. Currently the 
predominant material used by research groups for the fabrication of microfluidic systems in the poly 
(dimethylsiloxane) (PDMS) [15] despite the wealth of alternative fabrication materials, such as polymers, paper, 
silicon, etc. Processes using PDMS have been significantly refined since their original introduction to the lab on a 
chip community, with a wealth of demonstrated fabrication techniques and generic components found in the literature. 
However, PDMS is limited in its commercial application owing to the difficulty in up scaling of mass manufacturing 
and the relatively high cost compared to alternatives such as polymers. More critically, the intrinsic material properties 
of native PDMS can lead to affects such as evaporation, leeching and absorption of a flowed liquid sample [14] which 
perhaps makes it unsuitable for repeatable, robust microfluidic biological and chemical analysis applications. These 
limitations can be overcome through post processing of the material, but adds an additional backend processing stage 
and therefore makes it more undesirable for commercial manufacturing. This therefore begs the question to the 
research community over its continued prevalence in microfluidic applications and research efforts must either focus 
on the up-scaled manufacturing of PDMS or shift to a more intensive evaluation of alternative fabrication materials 
of choice for lab-on-a-chip application, such as low-cost polymers.
2.3 Standardization
The issue of standardization overlaps with several of the previous point surrounding the issue of fabrication, 
device functionality and materials using the manufacturing of a given lab-on-a-chip device. More specifically, there 
is no one standard/preferred material or fabrication technique both research and commercial efforts are geared towards. 
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Microfluidic solutions companies are found offering devices made from substrates such as glass, metals, polymers 
and elastomers, all of which require their own material specific fabrication techniques. This is in stark contrast to 
many successful large scale manufacturing processes, such as the microelectronics industry, where arguably silicon is 
the material of choice and fabrication techniques and backend processes have been refined and standardized to this 
substrate. There is a subtle irony in this example given that the initial techniques for lab-on-a-chip fabrication had 
been derived from the microelectronics processes. Whist the great diversity in material and fabrication selection allows 
for greater flexibility and innovation in terms of research endeavor, it greatly limits a standard material and technique 
reaching the mainstream for lab-on-a-chip manufacturing and is likely a contributing factor the slow commercial 
uptake of the technology. The other conflict of interest between academia and the commercial methodology is the 
tendency of academics to strive primarily to prove a given hypothesis, the so called proof-of-concept in a ‘single-chip’ 
experiment, before their attention is moved to the next hypothesis to prove [10]. This attitude has led to a failure of 
many investigations in the field failing to cite the reproducibility and chip-to-chip variability for a given material and 
fabrication method [1]. This tendency is at odds with production personnel who strive to achieve the greatest degree 
of batch-to-batch or chip-to-chip repeatability in terms of fabrication tolerances and performance, to give the end user 
the most standardized instrumentation possible. Indeed without this benchmark, many devices will be unsuccessful in 
the commercial arena, despite incorporating high levels of academic innovation, particularly in application of critical 
result endpoints such as in medical diagnostics. What is required is for academics to perhaps examine more closely 
the chip-to-chip variability and repeatability of use, to provide more statistically relevant results of not only their own 
work to support the ever increasingly popular claims of a devices potential for use in the real world, but to also aid 
manufacturers in determining the feasibility of producing a product using a particular design, fabrication technique or 
material.
2.4 The Added value
For a new lab-on-a-chip innovation to have high potential for commercialization and uptake as a routinely used 
instrumentation, the device must not only surpass the existing methodologies/devices in terms of performance, cost 
and usability, but in many instances must do so by at least one or two orders of magnitude in providing a solution of 
value to the end user. If the proposed device only offers more minor, incremental improvements for a particular 
applications, then the end users may be reluctant to uptake the technology over more tried and tested methods, where 
training and routes for data management are well defined. In many instances within the literature there appears to be 
a conflict of understanding between classical research based goals and the true added value a constructed device is 
providing within the context of the problem it is aimed at addressing. For example, the research community 
traditionally holds the ability to perform a test rapidly, or in the case of biosensors, with an increased sensitivity as the 
pinnacle benchmarks required to validate their systems superiority over existing methodologies. However, in some 
applications a device is aimed towards, there is no added value if a test was performed rapidly or not. For example in 
the case of genetic testing for disease there is no advantage to having the result within an hour as opposed to within 
several days as the outcome for the patient with ultimately be the same. Equally, the pursuit, of lower limits of 
detection (LLD) from a biosensor may be technologically impressive, but adds no value to a system if the target 
measurement range is generally significantly above that of the LLD. This conflict is further exemplified through some 
of the claims made by academics regarding the translational potential of lab-on-a-chip devices, where publications 
readily boast about the ‘low-cost’ and the ‘portability’ of their innovations in the context of a real world scenario, but 
there is a sense researchers don’t fully appreciate the true associated costs or value should such devices be considered 
commercially. Generally, in such work, while demonstrating high levels of innovation either operate under the ‘chip-
in-a-lab’ paradigm or the upscaling costs that include backend processes are not fully appreciated. Additionally, some 
devices may be guilty of engineering a capability which would not otherwise be required, for instance portable ‘in-
field’ measuring of environmental samples may not provide any advantage over simply analysing a sample in the 
laboratory as time is not critical to the measurement outcome. For the greatest degree of commercial success and 
added value of the technology, researchers should ideally focus their efforts into technologies which are only possible 
given the use of lab-on-a-chip. In other applications researchers must have a greater awareness in the initial 
engineering phases to create a lab-on-a-chip solution that address a ‘true’ market need and which draws upon the 
technology’s intrinsic advantages by which to provide a strategic advantage over existing methods. For instance, 
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medical scenarios where time has a critical impact on a patients wellbeing (cardiac biomarker detection) would benefit 
from a lab-on-a-chip platform to provide a result rapidly and in a portable manner, whereas the same would not be 
true for genetic testing of disease.
3. Conclusion
It is now increasingly obvious that research into lab-on-a-chip technology has reached a critical mass, where the 
abundant demonstrations of innovations need to move into the next phase of development into usable consumer 
products. This challenge will require a shift in the mind-set of researchers in the field to engage more with their 
industrial counterparts to realize a greater appreciation for the delicate balance of functionality, cost, sensitivity and 
device complexity with how this will translate to the economies of scale for mass manufacturing. This in itself is a 
non-trivial hurdle in the transferal of technology to the market. Ironically, it is believed that the reductionist approach 
may be required in stripping back lab-on-a-chip technology to its bare essentials for not only ease of manufacturing, 
but reducing chip-to-chip variations by minimizing the number of variables that negatively impact the efficacy of the 
final device. This approach is perhaps at odds with modern advancements in the field where researchers strive to 
demonstrate innovative functionalities at the trade-off of increased complexity, and ultimately, a reduced capacity for 
mass manufacturing. It is debatable whether there is such a thing as a single ‘killer application’ in lab-on-a-
chip/microfluidic technology but it seems abundantly apparent that through careful consideration by researchers to 
the challenges involved in commercialization, an appreciation of the end-user needs and the added value the 
technology provides for a particular application, such technology is likely to find greater prevalence and market 
penetration in the near future.
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